Clinical laboratories are reimbursed for providing services to Medicare beneficiaries using either the Physician Fee Schedule (PFS) or the Clinical Laboratory Fee Schedule (CLFS), depending on the nature of the service. In addition, clinical laboratories provide services to beneficiaries of other government programs such as Medicaid, TRICARE and the Federal Employee Health Benefit Plan (FEHBP),…
Clinical laboratories are reimbursed for providing services to Medicare beneficiaries using either the Physician Fee Schedule (PFS) or the Clinical Laboratory Fee Schedule (CLFS), depending on the nature of the service. In addition, clinical laboratories provide services to beneficiaries of other government programs such as Medicaid, TRICARE and the Federal Employee Health Benefit Plan (FEHBP), as well as commercial plans.
Lab reimbursement in many of these programs has been reduced in recent years, and in the case of the Medicare program, annual cuts are scheduled in current law not only as a result of sequestration, but also through annual cuts built into the Affordable Care Act.
While payments for lab services are being slashed, the costs associated with providing critical laboratory services - including labor, supplies, and transportation - continue to climb.
Although many labs have managed to navigate changes in markets and reimbursement and while still continually improving quality, continued arbitrary and severe payment reductions will result in reduced access to essential tests for critically ill patients, less innovation, more closures or consolidation of businesses, and more people out of jobs.
-
Reps. Pascrell and Meehan Dear Colleague on PAMA Proposed Rule
-
Senator Brown Dear Colleague on PAMA Proposed Rule
-
ACLA Calls on CMS to Modify the Protecting Access to Medicare Act (PAMA) Proposed Rule to Accurately Reflect Market Prices, Support Continued Innovation in Diagnostics
(WASHINGTON, DC) – The American Clinical Laboratory Association (ACLA) offered extensive comments today on the proposed rule addressing reimbursement methodology for clinical labs issued by ... Read More -
ACLA Comments on PAMA Proposed Rule
-
ACLA Letter to CMS on Reference Laboratory Claim Denials
-
ACLA Comments on MAAA Testing and Other Preliminary Determinations
-
ACLA Comments on DOA and Other Preliminary Determinations
-
ACLA Follow-up Letter to OIG Regarding AO 15-04
-
ACLA Letter to CMS on Drugs of Abuse Test Coding
-
ACLA Letter to Sean Cavanaugh on Medicare’s recent Policies and Procedures to Laboratory Procedures